Short Interest in Renovaro Inc. (NASDAQ:RENB) Rises By 30.7%

Renovaro Inc. (NASDAQ:RENB) was the recipient of a large increase in short interest during the month of December. As of December 31st, there was short interest totalling 5,060,000 shares, an increase of 30.7% from the December 15th total of 3,870,000 shares. Currently, 6.6% of the shares of the company are sold short. Based on an average daily volume of 1,030,000 shares, the days-to-cover ratio is presently 4.9 days.

Institutional Investors Weigh In On Renovaro

Hedge funds have recently made changes to their positions in the stock. SG Americas Securities LLC increased its stake in Renovaro by 193.3% during the fourth quarter. SG Americas Securities LLC now owns 51,725 shares of the company’s stock valued at $43,000 after acquiring an additional 34,090 shares during the period. JPMorgan Chase & Co. grew its holdings in shares of Renovaro by 347.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 93,010 shares of the company’s stock worth $45,000 after purchasing an additional 72,230 shares in the last quarter. Barclays PLC increased its position in shares of Renovaro by 315.7% during the third quarter. Barclays PLC now owns 69,531 shares of the company’s stock valued at $34,000 after purchasing an additional 52,804 shares during the period. State Street Corp raised its stake in shares of Renovaro by 3.8% in the third quarter. State Street Corp now owns 1,323,832 shares of the company’s stock valued at $640,000 after purchasing an additional 48,114 shares in the last quarter. Finally, Rhumbline Advisers bought a new position in Renovaro in the second quarter worth $79,000. Institutional investors own 71.41% of the company’s stock.

Renovaro Stock Down 5.7 %

Renovaro stock traded down $0.04 during mid-day trading on Friday, reaching $0.71. The company had a trading volume of 624,909 shares, compared to its average volume of 1,574,592. The firm has a market cap of $112.22 million, a price-to-earnings ratio of -0.74 and a beta of 0.66. The company has a 50 day moving average of $0.98 and a 200-day moving average of $0.85. Renovaro has a 52 week low of $0.40 and a 52 week high of $5.25.

Renovaro Company Profile

Renovaro Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company’s product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV.